📣 VC round data is live. Check it out!

AOTI Valuation Multiples

Discover revenue and EBITDA valuation multiples for AOTI and similar public comparables like Creo Medical Group, BioStem Technologies, Cumberland, Pentixapharm Holding and more.

AOTI Overview

About AOTI

AOTI Inc produces, rents, and sells medical devices to help resolve severe acute and chronic wounds for customers globally. The company provides efficacious topical wound oxygen solutions for use in both the institutional and the home care setting to improve the health, well-being, and independence of patients. Its products include TWO2 Extremity Chamber, TWO2 Multi-Patch.


Founded

2008

HQ

United States

Employees

N/A

Website

aotinc.net

Financials (FY)

Revenue: $67M
EBITDA: $8M

EV

$92M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

AOTI Financials

AOTI reported last fiscal year revenue of $67M and EBITDA of $8M.

In the same fiscal year, AOTI generated $58M in gross profit, $8M in EBITDA, and $3M in net income.


AOTI P&L

In the most recent fiscal year, AOTI reported revenue of $67M and EBITDA of $8M.

AOTI is profitable as of last fiscal year, with gross margin of 87%, EBITDA margin of 11%, and net margin of 4%.

See analyst estimates for AOTI
Last FY202320242025202620272028
Revenue$67M$44M$58M$67M
Gross Profit$58M$38M$51M$58M
Gross Margin87%86%88%87%
EBITDA$8M($4M)$3M$8M
EBITDA Margin11%(10%)5%11%
EBIT Margin8%(13%)2%8%
Net Profit$3M($8M)($2M)$3M
Net Margin4%(19%)(3%)4%
Net Debt$6M---

Financial data powered by Morningstar, Inc.

AOTI Stock Performance

AOTI has current market cap of $84M, and enterprise value of $92M.

Market Cap Evolution


AOTI's stock price is $0.79.

AOTI share price decreased by 34.0% in the last year.

AOTI has an EPS (earnings per share) of $0.03.

See more trading valuation data for AOTI
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$92M$84M0.1%0.0%66.7%-34.0%$0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

AOTI Valuation Multiples

AOTI trades at 1.4x EV/Revenue multiple, and 12.2x EV/EBITDA.

See NTM and 2027E valuation multiples for AOTI

AOTI Financial Valuation Multiples

As of June 3, 2026, AOTI has market cap of $84M and EV of $92M.

AOTI has a P/E ratio of 31.6x.

Last FY202320242025202620272028
EV/Revenue1.4x2.1x1.6x1.4x
EV/EBITDA12.2x(21.5x)34.9x12.2x
EV/EBIT16.6x(16.6x)73.3x16.6x
EV/Gross Profit1.6x2.4x1.8x1.6x
P/E31.6x(10.3x)(48.0x)31.6x
EV/FCF(13.9x)(33.3x)(11.7x)(13.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified AOTI Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

AOTI Margins & Growth Rates

In the most recent fiscal year, AOTI reported gross margin of 87%, EBITDA margin of 11%, and net margin of 4%.

See estimated margins and future growth rates for AOTI

AOTI Margins

Last FY20242025202720282029
Gross Margin87%88%87%
EBITDA Margin11%5%11%
EBIT Margin8%2%8%
Net Margin4%(3%)4%
FCF Margin(10%)(13%)(10%)

AOTI Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth33%14%
Gross Profit Growth37%13%
EBITDA Growth(162%)186%
EBIT Growth(123%)340%
Net Profit Growth(79%)(252%)
FCF Growth184%(16%)

Data powered by FactSet, Inc. and Morningstar, Inc.

AOTI Operational KPIs

Access forward-looking KPIs for AOTI
Last FY202320242025202620272028
Opex to Revenue79%98%86%79%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

AOTI Competitors

AOTI competitors include Creo Medical Group, BioStem Technologies, Cumberland, Pentixapharm Holding, Agfa-Gevaert, Sera Prognostics, Applied BioCode, electroCore, Vuno and FluoGuide.

Most AOTI public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Creo Medical Group13.6x7.4x(2.1x)(4.2x)
BioStem Technologies-1.5x--
Cumberland1.9x-28.8x-
Pentixapharm Holding692.8x-(4.1x)-
Agfa-Gevaert0.2x0.2x3.1x3.1x
Sera Prognostics431.9x157.6x(1.1x)(1.0x)
Applied BioCode4.2x-(13.9x)-
electroCore2.5x2.2x(9.1x)(10.5x)

This data is available for Pro users. Sign up to see all AOTI competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About AOTI

When was AOTI founded?AOTI was founded in 2008.
Where is AOTI headquartered?AOTI is headquartered in United States.
Who is the CEO of AOTI?AOTI's CEO is Michael Stephen Griffiths.
Is AOTI publicly listed?Yes, AOTI is a public company listed on London Stock Exchange.
What is the stock symbol of AOTI?AOTI trades under AOTI ticker.
When did AOTI go public?AOTI went public in 2024.
Who are competitors of AOTI?AOTI main competitors include Creo Medical Group, BioStem Technologies, Cumberland, Pentixapharm Holding, Agfa-Gevaert, Sera Prognostics, Applied BioCode, electroCore, Vuno, FluoGuide.
What is the current market cap of AOTI?AOTI's current market cap is $84M.
What is the current revenue of AOTI?AOTI's last fiscal year revenue is $67M.
What is the current EV/Revenue multiple of AOTI?Current revenue multiple of AOTI is 1.4x.
Is AOTI profitable?No, AOTI is not profitable.
How many companies AOTI has acquired to date?AOTI hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies AOTI has invested to date?AOTI hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to AOTI

Lists including AOTI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial